

BioCenturyExtra

THE BERNSTEIN REPORT ON BIOBUSINESS®

Article Reprint • Page 1 of 1

Top Story

Gloucester raises \$29 million

Gloucester Pharmaceuticals Inc. (Cambridge, Mass.) raised \$29 million in a series D round led by new investor Novo A/S. Existing investors Apple Tree Partners; ProQuest Investments; Prospect Venture Partners; and Rho Ventures also participated.

Gloucester's romidepsin is under FDA review to treat cutaneous T cell lymphoma (CTCL) with a Nov. 12 PDUFA date. The agency's Oncologic Drugs Advisory Committee will discuss the NDA for the histone deacetylase (HDAC) inhibitor on Sept. 2. Novo's Thomas Dyrberg will join Gloucester's board.

BioCentury®
THE BERNSTEIN REPORT ON BIOBUSINESS

PO Box 1246
San Carlos CA 94070-1246
Voice: 650-595-5333
Fax: 650-595-5589
www.biocentury.com

DAVID FLORES
President & CEO

KAREN BERNSTEIN, Ph.D.
Chairman & Editor-in-Chief

BioCentury®, The BioCentury 100, and The Clear Route are trademarks of BIOCENTURY PUBLICATIONS INC. All contents © Copyright 2009, BIOCENTURY PUBLICATIONS INC. ALL RIGHTS RESERVED. No part of this publication may be reproduced, photocopied or reproduced in any form, retransmitted, or stored in a retrieval system without prior written consent of the publisher.

The contents of this publication are gathered from sources believed to be reliable, but in any case are not warranted by the publisher for a particular use or purpose. Also, the content and opinions herein may change without notice and do not constitute investment advice.

XXX,
from previous page

